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258 www.jclinrheum.com JCR: Journal ocycles seem to have a better safety profile. Our objective was to describe the
pattern of use of rituximab in real-life practice conditions.
Methods: Rituximab for RA in clinical practice (RITAR) study is a retro-
spective cohort study from 2005 to 2015. Eligibility criteriawere RA adults
treated with rituximab for active articular disease. Response duration was
the main outcome defined as months elapsed from the date of rituximab
first infusion to the date of flare. A multivariable analysis was performed
to determine the variables associated with response duration.
Results: A total of 114 patients and 409 cycles were described, 93.0%
seropositive and 80.7% women. Rituximab was mainly used as second-line
biological therapy. On demand retreatment was used in 94.6% of cases
versus fixed 6 months retreatment in 5.4%. Median response duration
to on demand rituximab cycles was 10 months (interquartile range,
7–13). Multivariable analysis showed that age older than 65 years, number
of rituximab cycles, seropositivity, and first- or second-line therapy were
associated with longer response duration. The dose administered at each
cycle was not significantly associated with response duration.
Conclusions: Our experience suggests that 1000 mg rituximab single in-
fusion on demand is a reasonable schedule for long-term treatment of those
patients with good response after the first cycles, especially in seropositive
patients and when it is applied as a first- or second-line biological therapy.
Key Words: rheumatoid arthritis, rituximab, observational study
(J Clin Rheumatol 2019;25: 258–263)
R heumatoid arthritis (RA) is a chronic autoimmune diseasewith a heterogeneous genetic background whose pathogenesis
involves different cells of the immune system. Rituximab is a
B-lymphocyte depleting monoclonal antibody that was approved
for RA treatment in Europe in 2006. The approved indication in
this disorder is as a second-line biological therapy, which is for pa-
tients who have had an inadequate response or intolerance to 1 or
more tumor necrosis factor (TNF) inhibitor therapies, if possible
in combination with methotrexate (MTX). Nevertheless, EULAR
recommendations for RAmanagement, as well as other consensus
documents, suggest that rituximab can be used as a first-line bio-
logical therapy under certain circumstances.1,2
The schedule of rituximab retreatment administration remains
controversial. The summary of product characteristics suggests that
for RA 2 intravenous infusions of 1000mg, on days 1 and 15, should
be administered and then treatment can be repeated after 24 weeks.
This ambiguous statement is the consequence of early pivotal stud-
ies exploring both fixed retreatment and on demand schedules.3
Current evidence from clinical trials and registries challenges
the existence of relevant efficacy differences between dosing ri-
tuximab 1000 mg or 2000 mg per cycle, and the low-dose schedule
seems to have a better safety profile in terms of immunoglobulin G
count.4–6 In addition, rituximab is more effective in RA patients
seropositive for rheumatoid factor (RF) or anticitrullinated proteinf Clinical Rheumatology • Volume 25, Number 6, September 2019
JCR: Journal of Clinical Rheumatology • Volume 25, Number 6, September 2019 Rituximab Use for RA in Clinical Practiceantibodies (ACPAs).7,8 Considering these findings, the
Spanish Rheumatology Society and Hospital Pharmacy Society
Consensus for biologics optimization recommended the use of
1000 mg rituximab cycles on demand retreatment and preferen-
tially in RF or/and ACPA-seropositive patients.9
The rituximab for RA in clinical practice (RITAR) study objec-
tivewas to describe the pattern of use of rituximab in real-life practice
conditions over 11 years in our hospital. In addition, we collected in-
formation about clinical response duration in those cycles prescribed
on demand to identify factors associated with this outcome.
METHODS
Patients
RITAR is a retrospective, open-label, observational cohort
study that describes the patterns of use of rituximab in a tertiary
university hospital in Madrid, Spain, from 2005 to 2014 and a
follow-up period that covered until December 2015.
Eligibility criteriawere RA adults treated with at least 1 ritux-
imab infusion for articular active disease. Patients were identified
from the Hospital Pharmacy Department database, and clinical
charts were reviewed to confirm the RA diagnosis according to
the American College of Rheumatology 1987 criteria.10 Patients that
did not fulfill the criteria, those having a history of another autoim-
mune disease or RA patients in which rituximab was prescribed be-
cause of systemic complications, were excluded from the study.
Those rituximab cycles that were lost from follow-up and those cy-
cles administered under a clinical trial protocol were also excluded.
Data were retrospectively collected from our electronic med-
ical record software. During the study period and follow-up, treat-
ment decisions were taken under daily clinical practice criteria.
Patients treated with on demand RTX cycles have scheduled visits
at 3, 6, 8, 10, 12, and 14 months to early detect relapses. Some of
these visits are conducted by our specialized nurse. Patients have
also the possibility to contact the nurse by phone if they feel they
are relapsing, and then the nurse can provide them with an extra
appointment with the responsible physician.
RA Activity Measurements
DAS28 (disease activity score based on a 28-joint count) was
systematically registered at the time of rituximab infusion (base-
line visit of each cycle). However, because this is a retrospective
noninterventional study, some data required to assess disease ac-
tivity with objective measures (ie, DAS28) were missing in subse-
quent follow-up visits. Response duration was defined as the time
(in months) elapsed from the date of the first rituximab infusion to
the date of flaring (DAS28 > 3.2) recorded in the clinical chart. In
those cases in which there was no information on the date of flare,
the date of the next rituximab administration was used as the flare
date. Ineffectiveness was considered if the physician in charge of
the patient described absence of improvement of disease activity
or improvement lasting for less than 4 months. Information about
effectiveness was obtained from the data and commentaries in the
clinical chart.
Study Variables
For each rituximab cycle, we collected number of cycle, ri-
tuximab dose per cycle (1000 mg or 2000 mg), retreatment sched-
ule (fixed retreatment every 6months or on demand), concomitant
disease-modifying antirheumatic drugs (DMARDs), and number
of previous biological therapies. In case of rituximab discontinua-
tion, the reason for it was also collected (lack of effectiveness, ad-
verse reactions, and others). In addition, we recorded patient RF
or/and ACPA status at baseline.© 2018 The Author(s). Published by Wolters Kluwer Health, Inc.Additional Variables
Baseline characteristics of the patients were recorded, includ-
ing demographic characteristics (sex, age at disease onset, age at ri-
tuximab start) and presence of comorbidities (chronic obstructive
pulmonary disease, congestive heart disease, depression, diabetes
mellitus, gastric ulcer, hypercholesterolemia, hypertension, ische-
mic heart disease, osteoporosis, stroke, solid, or hematological neo-
plasms), shown in Supplemental Digital Content Table 1, http://
links.lww.com/RHU/A126, with patient’s comorbidities, and RA
systemic and extra-articular manifestations (amyloidosis, atlantoaxial
luxation, episcleritis, Felty syndrome, lung disease, rheumatoid
vasculitis, serositis, Sjögren syndrome) shown in Supplemental
Digital Content Table 2, http://links.lww.com/RHU/A127, with
complications associated to RA.
Concomitant DMARDs, previous nonbiological and biological
DMARDs,were also recorded including their biological line number,
dates of onset and withdrawal, as well as the main reason for dis-
continuation (lack or loss of effectiveness, adverse reactions, others).
Glucocorticoids and nonsteroid anti-inflammatory drugs, intra-
articular and periarticular glucocorticoid infiltrations, and other con-
comitant treatments are frequently used but were not registered.Ethical Statements
RITAR study was conducted according to the principles
expressed in the Helsinki Declaration of 1983. RITAR was con-
sidered by the Spanish Agency ofMedicines andMedical Devices
as an observational study, and it was approved by the Research
Ethics Committee of Hospital Universitario La Princesa (code
number 2903A), which did not consider necessary to ask for the
written consent of patients. Nevertheless, patients that continued
their follow-up at the Rheumatology Department were informed
about the study, and verbal consent was obtained.Statistical Analysis
For the description of the population means ± standard devi-
ation (SD), medians and interquartile range (IQR) and absolute
and relative frequencies were used depending on the distribution
of variables. Student t test was used for continuous variables with
normal distribution. Discrete variables or those continuous not
normally distributed were analyzed with theMann-WhitneyU test
or Kruskal-Wallis test, if more than 2 categories existed. Categor-
ical variables were analyzed with the χ2 test or Fisher test when
any expected frequency was lower than 1, or when 20% of the ex-
pected frequencies were 5 or less.
To determine which variables were associated with response
duration, and considering that we studied repeated measurements
(different rituximab cycles) for each patient, a multivariable analysis
using population-averaged panel data models through the com-
mand xtgee of Stata was used. This command allows fitting multi-
variable analysis using generalized estimation equations nested by
patient and cycle to adjust for repeated measurements. Adding all
variables with a p value less than 0.15 in the bivariate analysis per-
formed the first model. The final model was constructed through
backward stepwise method removing all variables with p greater
than 0.15 and also considering quasi-likelihood estimation based
on the independence model information criterion and Wald tests.11
In addition, to estimate the average response duration of 1000 mg
and 2000 mg rituximab cycles, we forced this variable in the final
model, and then the adjusted mean ± standard error were estimated
with the xtgee postestimation command margins. Statistical analy-
ses were performed using the statistical package Stata v. 12.www.jclinrheum.com 259
Cañamares et al JCR: Journal of Clinical Rheumatology • Volume 25, Number 6, September 2019RESULTS
Patients
One hundred sixty-one patients were treated with rituximab.
Eighteen patients treated under other diagnoses different from
RA, 8 patients in whom rituximab was prescribed because of
RA systemic manifestations, and 21 patients who were not
followed up in our hospital after the first rituximab infusion were
excluded. In addition, those rituximab cycles that belonged to
clinical trials or were lost during follow-up were excluded from
the analysis. Finally, 114 patients were included and 409 rituxi-
mab cycles were described. Median follow-up was 2.95 years
(IQR, 1.24–5.54).
Age at rituximab start was 60 years (IQR, 51–69) and disease
duration was 11 years (IQR, 6–16). Most patients experienced se-
ropositive disease (93%) and 80.7% of them were women. Be-
cause, after approval of rituximab, new biological therapies
became available for RA treatment, we decided to cluster patients
in 3 groups considering the year of rituximab start (before 2009,
2009–2011, and 2012–2014). As it is shown in Table 1, patients
treatedwith rituximab before 2009were younger and seronegative
cases were more frequent. In addition, those treated after 2012
tended to suffer less comorbidities (p = 0.018) and systemic com-
plications (p = 0.119). No differences were observed in terms of
previous DMARDs, biological therapies, or disease activity at
the beginning of treatment.
Patterns of Rituximab Use
As it is shown in Table 1, rituximab was mainly used as
second-line biological therapy. Nevertheless, rituximab was the
first biological treatment in 19.3% of overall cases, with tendency
to be less frequent since 2012 and more common among those
patients who received more rituximab cycles (Table 1). Previous
therapies to rituximab treatment start are shown in Supplemental
Digital Content 3, http://links.lww.com/RHU/A112. Median number
of rituximab cycles per patient was 3 (IQR, 2–6), ranging from 1 to 11.TABLE 1. Baseline Characteristics of Patients
RTX Start Yea
≤2008
(n = 49)
2009−2011
(n = 38)
201
(n
Female, n (%) 38 (77.6%) 31 (81.6%) 23
Age at disease onset, p50 (IQR), y 41 (38–53) 54 (42–63) 54
Age at RTX start, p50 (IQR), y 56 (47–64) 64 (55–74) 60
RA complications, n (%)
0 29 (59.1%) 19 (50.0%) 20
1–2 19 (38.8%) 19 (50.0%) 6
>2 1 (2.1%) 0 (0.0%) 1
Comorbidities, n (%)
0–1 36 (73.5%) 23 (60.5%) 25
≥2 13 (26.5%) 15 (39.5%) 2
RF and/or ACPA positive (%) 43 (87.8%) 38 (100%) 25
Previous DMARDs, p50 (IQR) 2 (1–3) 2 (1–3) 2
Previous BT, p50 (IQR) 1 (1–2) 1 (1–2) 1
RTX as first biologic-line therapy, n (%) 10 (20.4%) 9 (23.7%) 3
DAS28 at cycle 1, p50 (IQR) 5.3 (4.8–6.0) 5.4 (4.7–6.0) 5.3
HAQ at cycle 1, p50 (IQR) 1.5 (0.8–1.6) 1.3 (0.8–1.8) 1.1
p50 indicates 50th percentile or median; BT, biological therapies; HAQ, He
260 www.jclinrheum.comOn demand retreatment schedule was used in 94.6% of total
rituximab cycles versus fixed retreatment every 6 months in 5.4%.
Rituximab fixed retreatment was more frequent during the first years
of rituximab use in our center (until 2008 12% of cycles), but this
pattern of use gradually decreased (7.9% of cycles 2009–2011)
and disappeared after 2012. In addition, fixed retreatment schedule
was more common in the initial courses of treatment reaching
12.5% at first cycle, 6.9% at second, 3.3% at third, and 2.0% at
fourth or later. For those patients receiving 5 or more cycles, the
on demand schedule was always used.
Rituximab dose was 1  1000 mg in 31.8% of total cycles.
There were no relevant differences in the percentage of 1000 mg
and 2000 mg cycles over time (p = 0.151). However, we observed
that the use of 1  1000 mg cycles was significantly more fre-
quent in cycle 3 or successive (45%) compared with the 2 first cy-
cles (17%; p < 0.001). Specifically, in 91.5% of first rituximab
cycles dose was 2000 mg. Then, the use of rituximab 1000 mg
per cycle gradually increased up to 80% to 100% in those patients
with more than 6 cycles.
Rituximabwas used without concomitant DMARDs in 12.2%
of patients, and the use as monotherapy gradually increased over
time (Table 2). Regarding concomitant DMARD treatment, the
most frequent was MTX (53.8%), followed by leflunomide (36.7%),
hydroxychloroquine (7.6%), sulfasalazine (2.9%), and others
(azathioprine and cyclosporine, 7.6%). In 16.2% of the cycles,
concomitant DMARDs were used in combination, being MTX
plus leflunomide the most frequent.
Response Duration
As it is shown in Figure 1A, there was an average disease ac-
tivity improvement after rituximab administration at each cycle,
although the degree of response was clearly heterogeneous. In ad-
dition, Figure 1B shows that baseline disease activity was the
worst at the first rituximab cycle. Then, although most of the suc-
cessive rituximab cycles were prescribed on demandwhen the dis-
ease flared, on average, retreatment was administered with lower
levels of disease activity than the first cycle.r RTX Cycle Number Total
2−2014
= 27) p value
n ≤ 2
(n = 46)
n ≥ 3
(n = 68) p value (n = 114)
(85.2%) 0.720 37 (80.4%) 55 (80.8) 1.000 92 (80.7%)
(42–57) 0.012 54 (41–62) 46 (39–56) 0.041 50 (40–59)
(54–67) 0.061 64 (52–70) 58 (49–66) 0.096 60 (51–69)
(74.1%) 0.119 30 (65.2%) 38 (55.9%) 0.431 68 (59.7%)
(22.2%) 16 (34.8%) 28 (41.2%) 44 (38.6%)
(3.7%) 0 (0.0%) 2 (2.9%) 2 (1.75%)
(93.6%) 0.012 33 (71.4%) 51 (75.0%) 0.829 84 (73.7%)
(7.4%) 13 (28.3%) 17 (25.0%) 30 /26.3%)
(93.6%) 0.065 41 (89.1%) 65 (95.6%) 0.265 106 (92.8%)
(1–3) 0.287 2 (1–3) 2 (1–3) 0.754 2 (1–3)
(1–2) 0.654 2 (1–2) 1 (1–2) 0.692 1 (1–2)
(11.1%) 0.289 7(15.2%) 15 (22.1%) 0.066 22 (19.3%)
(4.6–5.7) 0.576 5.1 (4.6–5.9) 5.4 (4.8–6.0) 0.228 5.3 (4.7–5.9)
(0.8–1.8) 0.940 1 (0.6–1.6) 1.6 (0.8–1.8) 0.355 1 (0.5–1.6)
alth Assessment Questionnaire.
© 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
TABLE 2. Concomitant DMARDs in Rituximab Cycles
RTX by Start Year RTX by Cycle Number Total
≤2008
(n = 225)
2009−2011
(n = 129)
2012−2014
(n = 55) p value
n ≤ 2
(n = 194)
n ≥ 3
(n = 215) p value (n = 114)
MTX 116 (51.6%) 62 (48.1%) 33 (60.0%) 0.337 102 (52.9%) 109 (50.7%) 0.766 211 (51.6%)
Leflunomide 73 (32.4%) 58 (45.0%) 15 (27.3%) 0.024 67 (34.5%) 79 (36.7%) 0.680 146 (35.7%)
Hydroxychloroquine 22 (9.8%) 7 (5.4%) 2 (3.6%) 0.187 14 (7.2%) 17 (7.9%) 0.853 31 (7.6%)
Sulfasalazine 0 (0.0%) 11 (8.5%) 1 (1.8%) 0.000 6 (3.1%) 6 (2.8%) 1.000 12 (2.9%)
Other DMARDs 7 (3.1%) 3 (2.3%) 0 (0.0%) 0.544 7 (3.6%) 3 (1.4%) 0.203 10 (2.4%)
RTX monotherapy 25 (11.1%) 20 (15.5%) 13 (23.6%) 0.054 33 (17.0%) 25 (11.6%) 0.155 58 (14.2%)
RTX indicates rituximab; Other DMARDs, cyclosporine, azathioprine.
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314 cycles administered on demand. Median response duration
was 10 months (IQR, 7–13). Because there were some differences
in the use of rituximab along the 3 periods, we decided to perform
a multivariable analysis to determine which variables better ex-
plained response duration in our study. The best-fitted model
(Table 3) showed that older age and higher number of rituximab
cycles were significantly associated with longer response dura-
tion. Of interest, response duration was almost 3 months shorter
in seronegative than in seropositive patients, although the differ-
ences did not reach statistical significance (Table 3). Finally, when
rituximab was used as the third or even later line of biological
therapy, the response duration was almost 2 months shorter than
in those cycles in which rituximab was used as first or second line,
although statistical significance was not reached (Table 3).
Interestingly, the variable dose per cyclewas not significantly
associated with response duration. Furthermore, we estimated the
mean response duration for 1000 mg and 2000 mg rituximab cy-
cles adjusted for the variables included in the model shown in
Table 3. As Figure 2 shows, the differences in response duration
were negligible. Other variables such as sex, date of rituximab
start, or use in monotherapy were not associated with response
duration either. Nevertheless, female sex and use of rituximab
in monotherapy showed a trend to lower response durationFIGURE 1. Evolution of disease activity with rituximab treatment in RITA
B, Baseline disease activity at different rituximab cycles. Data are present
p50 midline), p95 (line above the box), and p5 (line below the box). Do
the nptrend Stata command, which is an extension of the Wilcoxon rank
ordered groups.
© 2018 The Author(s). Published by Wolters Kluwer Health, Inc.(Supplemental Digital Content 4, http://links.lww.com/RHU/
A128).When rituximab was used in combination with DMARDs,
there were no relevant differences between the different drugs.
Reasons for Rituximab Withdrawal
Of 114 patients that started rituximab because of active RA,
60 (52.6%) were still under this treatment at December 2015, with
a median follow-up of 4.80 years (IQR, 2.15–7.17). Withdrawal
from rituximab was due to ineffectiveness in 18.4% of cases
(n = 21), adverse events in 7.0% (n = 8), and other reasons such as
lost follow-up or non–rituximab-related deaths in 22.0% (n = 25).
Focusing on discontinuation caused by ineffectiveness, 71.4%
patients stopped after first or second rituximab cycles (n = 15),
23.8% after 3 to 5 cycles (n = 5) and 1.8% afterward (n = 1)
(p = 0.002). Biological line in which rituximab was used did not
seem to be related with ineffectiveness as the reason for
discontinuation (p = 0.805).
DISCUSSION
RITAR, a real-life observational study that described differ-
ent rituximab strategies used during 11 years, provides significant
information about how the use of this drug has evolved in our cen-
ter since its approval for RA treatment. We observed a tendency toR. A, Average disease activity assessed with DAS28 by follow-up visit.
ed as interquartile range (p75 upper edge, p25 lower edge,
ts represent the outliers. Statistical significance was estimated with
-sum test that performs a nonparametric test for trend across
www.jclinrheum.com 261
FIGURE 2. Response duration by dose of rituximab. Data are shown
as the prediction of themean response duration inmonths (top of
the histograms) and its 95% confidence intervals (bars) adjusted by
the relevant variables included in the multivariable analysis provided
in Table 3 (for further information, see Statistical Analysis section).
Cañamares et al JCR: Journal of Clinical Rheumatology • Volume 25, Number 6, September 2019abandon the fixed retreatment every 6 months schedule in favor of
the on demand use. In addition, the recommended rituximab dose
of 2000 mg per cycle was frequently replaced by 1000 mg per cy-
cle administered as a single infusion, especially beyond the third
cycle. The most frequent pattern consisted on starting rituximab
2000 mg in the first and second cycles and then reducing to ritux-
imab 1000 mg per cycle in successive retreatments. The main rea-
sons for this schedule are cost-saving and the attempt to reduce
adverse effects such as hypogammaglobulinemia and infections.12
This strategywas similar to that used in the SMART trial, a French
study that demonstrated noninferiority in different rituximab
schedules: 2000 mg per cycle versus a first course rituximab
2000 mg followed by rituximab 500 mg  2 in the consecutive
ones.5 In addition, a meta-analysis supported similar efficacy of
low- versus high-dose rituximab in different subsets of patients.4
Comparing to SMART strategy, RITAR treatment schedule has
advantages in terms of better cost-effectiveness13 and patient com-
fort, because low-dose cycles were administered as a single infu-
sion instead of 2 infusions of 500 mg.5
Rituximab was mainly used as second-line biological ther-
apy. Nevertheless, rituximabwas prescribed as first-line biological
therapy in 1 of 5 patients, which is a remarkable proportion. We
could not determine the reasons for this; probably cost-saving,
anti-TNF contraindication, and preference due to patient lifestyle
are some of the possibilities. In any case, recently, the ORBIT trial,
a head-to-head adalimumab versus rituximab randomized con-
trolled study, showed that rituximab is noninferior to TNF inhibi-
tors in patients naive to biological treatment.14 In addition, in a
long-term Finnish study, almost 28% of patients had never used
biologics before rituximab.15
In our study, rituximab was widely administered with 1 or
more concomitant DMARDs being the most frequently used
MTX and/or leflunomide. Previous evidence supports the use of
leflunomide in this context.2,16 Twelve percent of our rituximab
cycles were prescribed without concomitant DMARD. This is
lower than another Spanish cohort in which rituximab monother-
apy was used in 29% of patients.17 Interestingly, rituximab mono-
therapy has increased in our center from 11.1% to 23.6% in recent
years. The reasons for this trend are unclear and should be ana-
lyzed, because lower response magnitude and duration have been
described when rituximab is used as monotherapy.18TABLE 3. Variables Associated With Response Duration
(Months) to Rituximab
β-coefficient (95% CI) p value
Age at RTX start, y
<45 Reference —
45–65 2.32 (−0.49 to 5.13) 0.106
>65 3.63 (0.71 to 6.56) 0.015
Total no. RTX cycles administered
<3 Reference —
≥3 2.01 (0.66 to 3.35) 0.004
RF and/or ACPA status
Negative Reference —
Positive 2.69 (−0.44 to 5.82) 0.092
No. previous biological therapies
<3 Reference —
≥3 −1.83 (−3.77 to 0.12) 0.065
CI indicates confidence interval; RTX, rituximab.
262 www.jclinrheum.comAverage rituximab response duration in our patients was
10 months, which is in agreement with the data reported in the lit-
erature, ranging from 8.5 months in SMART5 and RESET19 trials
to 11 to 13 months observed in a long-term real-life Finnish
study.15 However, the longer time to retreatment in Finnish pa-
tients led to disease flare in a significant proportion of patients.
The SMART study showed a time to retreatment 1 month shorter
than ours, but a similar time to retreatment in the rituximab
1000 mg course (8.6 months) than in 2000 mg per cycle strategy
(8.4 months) in the 2-year follow-up. This later finding has also
been observed in our study.
In our multivariable model, the variables significantly associ-
ated with longer response duration were cycles later than second
and age higher than 65 years. These are likely indication biased be-
cause those patients with the worst response to rituximab were
withdrawn before the third cycle. In addition, we probably delayed
rituximab retreatment in elderly patients because of safety reasons.
Additional variables associated to a trend to longer response
duration in our study were seropositivity (RF and/or ACPA) and
previous treatment with 2 or less biological therapies. On average,
seropositive patients showed 3 months longer response duration
than seronegative ones. This is in accordance with previous stud-
ies.7,8,17 It is feasible that the pathogenesis of RA in those patients
with autoantibodies is more dependent on B-cells, thus explaining
their better response to rituximab.3 Furthermore, those patients
that received 3 or more previous biological lines experienced al-
most 2 months shorter response duration than those that were
treated with rituximab in an earlier biological line. This is again
in agreement with previous reports and the well-known lower re-
sponse to RA treatments in more refractory patients.17
Our study has some limitations commonly present in retro-
spective observational studies: missing data, high percentage of
unexplained lost cycles from follow-up, indication bias, and so
on. However, this kind of study offers complementary information
to that obtained in clinical trials, because observational studies are
able to provide data from real-life patients that are excluded from
clinical trials and schedules of treatment that are different from the
conventional approved ones.
In summary, our data suggest that, after a successful first cycle
of 2000 mg, retreatments with rituximab can be scheduled as
cycles of 1000 mg single infusion, because a lower number of
B-lymphocytes are detected at early phases of relapse when this
drug is used on demand (Lopez et al, unpublished data). In our ex-
perience, this retreatment schedule provides median response dura-
tion of 10 months, resulting in a comfortable schedule of treatment© 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
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mab use in seropositive patients, especially if it is applied as first or
second biological line, seems to provide longer response duration.
KEY POINTS
Rituximab 1  1000 mg cycles in on demand retreatment
schedule is useful for maintaining response in responder RA pa-
tients, providing median response duration of 10 months.
Patients older than 65 years, seropositive disease, and rituxi-
mab use in first or second biological line seem to result in longer
response duration.
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